Cargando…

Improving to Four or Fewer Monthly Headache Days Per Month Provides a Clinically Meaningful Therapeutic Target for Patients with Chronic Migraine

INTRODUCTION: Treatment target goals for patients receiving preventive migraine treatment are complicated to assess and not achieved by most patients. A headache “number” could establish an understandable treatment target goal for patients with chronic migraine (CM). This study investigates the clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaniecki, Robert G., Friedman, Deborah I., Asher, Divya, Hirman, Joe, Cady, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444931/ https://www.ncbi.nlm.nih.gov/pubmed/37378754 http://dx.doi.org/10.1007/s40122-023-00525-x

Ejemplares similares

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache
por: Marmura, Michael J., et al.
Publicado: (2021)

Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
por: Dodick, David W., et al.
Publicado: (2020)

Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies
por: Smith, Timothy R., et al.
Publicado: (2021)

Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine
por: McAllister, Peter, et al.
Publicado: (2022)

Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
por: Apelian, Rami, et al.
Publicado: (2022)

Eptinezumab for migraine prevention in patients 50 years or older
por: Martin, Vincent, et al.
Publicado: (2022)

Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study
por: Cowan, Robert P., et al.
Publicado: (2022)

Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT‐6) Total and Item‐Specific Scores in Chronic Migraine
por: Houts, Carrie R., et al.
Publicado: (2020)

Burden of Illness Among People with Migraine and ≥ 4 Monthly Headache Days While Using Acute and/or Preventive Prescription Medications for Migraine
por: Buse, Dawn C., et al.
Publicado: (2020)

Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas
por: Irimia, P., et al.
Publicado: (2021)

Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
por: Blumenfeld, Andrew, et al.
Publicado: (2022)

EHMTI-0108. Efficacy of therapy in patients with migraine: comparison in group of < 9 migraines and > 10 migraines per month
por: Cvetkovic, V Vukovic, et al.
Publicado: (2014)

Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
por: Ashina, Messoud, et al.
Publicado: (2022)

Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
por: Pozo-Rosich, Patricia, et al.
Publicado: (2022)

Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine
por: Buse, Dawn C., et al.
Publicado: (2022)

60. A Comparison of Outcomes in Trigger Site Deactivation Surgery: A Systematic Review and Meta-analysis of the Migraine Headache Index versus Monthly Migraine Days
por: Ormseth, Benjamin, et al.
Publicado: (2023)

Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome
por: Lipton, Richard B., et al.
Publicado: (2021)

Meaningful Memory? Eighteen-Month-Olds Only Remember Cartoons With a Meaningful Storyline
por: Sonne, Trine, et al.
Publicado: (2018)

A Case of Extra-Uterine Pregnancy of Four Months, Delivered per Uterus
por: Carhart, J. W.
Publicado: (1891)

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
por: Lipton, Richard B., et al.
Publicado: (2020)

Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo‐controlled randomized clinical trials
por: Schim, Jack D., et al.
Publicado: (2022)

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
por: Ashina, Messoud, et al.
Publicado: (2020)

Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
por: Kudrow, David, et al.
Publicado: (2021)

The Relationship Between Androgens and Days per Month of Period Pain, Pelvic Pain, Headache, and TLR4 Responsiveness of Peripheral Blood Mononuclear Cells in Young Women with Dysmenorrhoea
por: Evans, Susan F, et al.
Publicado: (2021)

Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
por: Silberstein, Stephen, et al.
Publicado: (2020)

Four-fermi theories in fewer than four dimensions
por: Hands, S, et al.
Publicado: (1993)

Fresh news as meaningful? A multi‐site ethnographic analysis of meaningful activities at four day centres in Denmark and Norway
por: Øye, Christine
Publicado: (2022)

Birth Month and Cardiovascular Disease Risk Association: Is meaningfulness in the eye of the beholder?
por: Poltavskiy, Eduard, et al.
Publicado: (2016)

Success in four months
Publicado: (1959)

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days
por: VanderPluym, Juliana, et al.
Publicado: (2018)

The Effect of Propofol Anesthesia on the Pain Severity and Frequency of Migraine Attacks in Patients with Chronic Migraine Headache over a Six Month Follow Up: An Observational Study
por: Vosoughian, Maryam, et al.
Publicado: (2021)

Early Child Development Outcomes of a Randomized Trial Providing 1 Egg Per Day to Children Age 6 to 15 Months in Malawi
por: Prado, Elizabeth L, et al.
Publicado: (2020)

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
por: Smith, Timothy R., et al.
Publicado: (2021)

Caffiene in Headache, (Migraine.)
por: Smith, T. Curtis
Publicado: (1874)

Migraine headache in Sudan
por: Ibrahim, Etedal Ahmed A., et al.
Publicado: (2021)

Migraine and Sick Headache
Publicado: (1905)

Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
por: Smith, Timothy R., et al.
Publicado: (2021)

An examination of periodontal treatment and per member per month (PMPM) medical costs in an insured population
por: Albert, David A, et al.
Publicado: (2006)

EGEE project sustains a million jobs per month
Publicado: (2006)

Reliability and validity of the 6-item Headache Impact Test in chronic migraine from the PROMISE-2 study
por: Houts, Carrie R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4t93fkrq60mseu12vrdeju9d43